Key facts
- Presentient’s last known valuation is $10.2M (Dec 2025).
- It has raised $3.3M; the latest was Early Stage VC ($2.8M) in Dec 2025.
- Notable investors include Creative Destruction Lab, DayOne Accelerator, Defined, Epiphany Capital, Episode 1 Ventures — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Presentient
- ·The full record, as it builds
Funding rounds
No funding rounds for Presentient are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Presentient
Developer of a novel data analysis platform designed to provide actionable insights. The company's platform can process large datasets for bloodwork, biomarker, and time-series data types and solve challenging problems, such as low-bias cluster analysis on complete patient-level data clustered by functional characteristics, enabling pharmaceutical and drug development companies to use projected trial outcomes from quarterly live trial data to inform decision-making.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2022
- Employees
- 8
- Website
- presentient.com/
- Ownership
- Privately Held (backing)
Presentient doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Presentient shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Presentient in its N-PORT filings yet. We sweep new filings monthly.